

Carlos M Ferrario

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7560268/carlos-m-ferrario-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

332
papers

19,798
citations

75
h-index

128
g-index

360
ext. papers

21,246
ext. citations

5
avg, IF

6.74
L-index

#	Paper	IF	Citations
332	The renin-angiotensin system biomolecular cascade: a 2022 update of newer insights and concepts.. <i>Kidney International Supplements</i> , 2022 , 12, 36-47	6.3	4
331	Immunoneutralization of human angiotensin-(1-12) with a monoclonal antibody in a humanized model of hypertension.. <i>Peptides</i> , 2021 , 149, 170714	3.8	2
330	Angiotensin (1-12) in Humans With Normal Blood Pressure and Primary Hypertension. <i>Hypertension</i> , 2021 , 77, 882-890	8.5	10
329	Commentary on: Renin-angiotensin system overactivation in perivascular adipose tissue contributes to vascular dysfunction in heart failure. <i>Clinical Science</i> , 2021 , 135, 683-686	6.5	
328	Letter to the Editor: Brain renin-angiotensin system and liver-directed siRNA targeted to angiotensinogen. <i>Clinical Science</i> , 2021 , 135, 907-910	6.5	3
327	Newly developed radioimmunoassay for Human Angiotensin-(1-12) measurements in plasma and urine. <i>Molecular and Cellular Endocrinology</i> , 2021 , 529, 111256	4.4	5
326	The Angiotensin-(1-12)/Chymase axis as an alternate component of the tissue renin angiotensin system. <i>Molecular and Cellular Endocrinology</i> , 2021 , 529, 111119	4.4	6
325	Atrial appendage angiotensin-converting enzyme-2, aging and cardiac surgical patients: a platform for understanding aging-related coronavirus disease-2019 vulnerabilities. <i>Current Opinion in Anaesthesiology</i> , 2021 , 34, 187-198	2.9	1
324	Estrogen receptors are linked to angiotensin-converting enzyme 2 (ACE2), ADAM metallopeptidase domain 17 (ADAM-17), and transmembrane protease serine 2 (TMPRSS2) expression in the human atrium: insights into COVID-19. <i>Hypertension Research</i> , 2021 , 44, 882-884	4.7	8
323	Amplifying effect of chronic lisinopril therapy on diastolic function and the angiotensin-(1-7) Axis by the G1 agonist in ovariectomized spontaneously hypertensive rats. <i>Translational Research</i> , 2021 , 235, 62-76	11	1
322	Chronic GPR30 agonist therapy causes restoration of normal cardiac functional performance in a male mouse model of progressive heart failure: Insights into cellular mechanisms. <i>Life Sciences</i> , 2021 , 285, 119955	6.8	1
321	Differential Expression of the Angiotensin-(1-12)/Chymase Axis in Human Atrial Tissue. <i>Journal of Surgical Research</i> , 2020 , 253, 173-184	2.5	9
320	Atrial angiotensin-(1-12)/chymase expression data in patient of heart diseases. <i>Data in Brief</i> , 2020 , 31, 105744	1.2	5
319	Reduced Left Atrial Emptying Fraction and Chymase Activation in Pathophysiology of Primary Mitral Regurgitation. <i>JACC Basic To Translational Science</i> , 2020 , 5, 109-122	8.7	4
318	Is hypertension in African-descent populations contributed to by an imbalance in the activities of the ACE2/Ang-(1-7)/Mas and the ACE/Ang II/AT axes?. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2020 , 21, 1470320320908186	3	13
317	Mechanisms by which angiotensin-receptor blockers increase ACE2 levels. <i>Nature Reviews Cardiology</i> , 2020 , 17, 378	14.8	22
316	Abstract 12677: Impaired Cardiomyocyte Contractility to Angiotensin-(1-12) in a Humanized Angiotensinogen Model of Hypertension. <i>Circulation</i> , 2020 , 142,	16.7	1

315	Therapeutic Nrf2 Activation improves LV function in the cardiomyocyte-specific GPER knockdown mouse. <i>FASEB Journal</i> , 2020 , 34, 1-1	0.9	
314	Twenty years of progress in angiotensin converting enzyme 2 and its link to SARS-CoV-2 disease. <i>Clinical Science</i> , 2020 , 134, 2645-2664	6.5	6
313	Noncanonical Mechanisms for Direct Bone Marrow Generating Ang II (Angiotensin II) Predominate in CD68 Positive Myeloid Lineage Cells. <i>Hypertension</i> , 2020 , 75, 500-509	8.5	8
312	Commentary on "angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic". <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020 , 14, 1401-1402	8.9	
311	Is Sex a Determinant of COVID-19 Infection? Truth or Myth?. <i>Current Hypertension Reports</i> , 2020 , 22, 62	4.7	12
310	Reversal of angiotensin-(1-12)-caused positive modulation on left ventricular contractile performance in heart failure: Assessment by pressure-volume analysis. <i>International Journal of Cardiology</i> , 2020 , 301, 135-141	3.2	6
309	Molecular Signaling Mechanisms of the Renin-Angiotensin System in Heart Failure 2020 , 76-90.e4		0
308	Mast cell peptidases (carboxypeptidase A and chymase)-mediated hydrolysis of human angiotensin-(1-12) substrate. <i>Biochemical and Biophysical Research Communications</i> , 2019 , 518, 651-656	3.4	5
307	Estrogen modulates the differential expression of cardiac myocyte chymase isoforms and diastolic function. <i>Molecular and Cellular Biochemistry</i> , 2019 , 456, 85-93	4.2	4
306	NLRP3 inhibition improves heart function in GPER knockout mice. <i>Biochemical and Biophysical Research Communications</i> , 2019 , 514, 998-1003	3.4	8
305	Female Heart Health: Is GPER the Missing Link?. <i>Frontiers in Endocrinology</i> , 2019 , 10, 919	5.7	21
304	Equivalence of G1/GPER Monotherapy Compared with Dual Administration of G1 and Lisinopril in Preventing Diastolic Dysfunction due to Estrogen Loss in SHR. <i>FASEB Journal</i> , 2019 , 33, 532.5	0.9	1
303	Estrogen Modulates the Differential Expression of Cardiac Myocyte Chymase Isoforms and Diastolic Function. <i>FASEB Journal</i> , 2019 , 33, 576.1	0.9	
302	Primacy of Chymase over Angiotensin Converting Enzyme in the Production of Angiotensin II in Rat Bone Marrow Tissue. <i>FASEB Journal</i> , 2019 , 33, 577.3	0.9	
301	Angiotensin-(1-7) and the Heart 2019 , 83-104		1
300	Activation of the Human Angiotensin-(1-12)-Chymase Pathway in Rats With Human Angiotensinogen Gene Transcripts. <i>Frontiers in Cardiovascular Medicine</i> , 2019 , 6, 163	5.4	13
299	Angiotensin-(1-12)/chymase axis modulates cardiomyocyte L-type calcium currents in rats expressing human angiotensinogen. <i>International Journal of Cardiology</i> , 2019 , 297, 104-110	3.2	5
298	Edward D. Frohlich, MD: September 10, 1931-August 16, 2019. <i>Hypertension</i> , 2019 , 74, 1229-1231	8.5	

297	G-Protein-Coupled Estrogen Receptor Agonist G1 Improves Diastolic Function and Attenuates Cardiac Renin-Angiotensin System Activation in Estrogen-Deficient Hypertensive Rats. <i>Journal of Cardiovascular Pharmacology</i> , 2019 , 74, 443-452	3.1	7
296	Critical role of the chymase/angiotensin-(1-12) axis in modulating cardiomyocyte contractility. <i>International Journal of Cardiology</i> , 2018 , 264, 137-144	3.2	10
295	Multifunctional Role of Chymase in Acute and Chronic Tissue Injury and Remodeling. <i>Circulation Research</i> , 2018 , 122, 319-336	15.7	56
294	G protein-coupled estrogen receptor (GPER) deficiency induces cardiac remodeling through oxidative stress. <i>Translational Research</i> , 2018 , 199, 39-51	11	25
293	Blunting of estrogen modulation of cardiac cellular chymase/RAS activity and function in SHR. <i>Journal of Cellular Physiology</i> , 2018 , 233, 3330-3342	7	12
292	The Renin-Angiotensin System and the Heart 2018 , 43-55		1
291	The Mitochondrial-targeted Antioxidant MitoQ Attenuates LV Dysfunction and Gene Expression Related to Oxidative Stress in Cardiomyocyte-specific GPER KO Female Mice. <i>FASEB Journal</i> , 2018 , 32, 618.20	0.9	
290	GPER Agonist G1, but Not Other Specific ERs Improves Diastolic Function and Attenuates Cardiac RAS Activation in Estrogen-deficient SHR. <i>FASEB Journal</i> , 2018 , 32, 584.2	0.9	
289	Development of Isolated Diastolic Dysfunction Associated with Early Impairment in Coronary Blood Flow in Hypertensive Diabetes. <i>FASEB Journal</i> , 2018 , 32, 903.5	0.9	
288	Knockdown of GPER in Cardiomyocytes Activates NLRP3 Pathways. <i>FASEB Journal</i> , 2018 , 32, 718.4	0.9	
287	A16670 Development of a Transgenic Rat Expressing the Human Chymase Gene to Study Human Cardiovascular Disease. <i>Journal of Hypertension</i> , 2018 , 36, e87-e88	1.9	
286	Chymase inhibitors for the treatment of cardiac diseases: a patent review (2010-2018). <i>Expert Opinion on Therapeutic Patents</i> , 2018 , 28, 755-764	6.8	14
285	Effect of Age, Estrogen Status, and Late-Life GPER Activation on Cardiac Structure and Function in the Fischer344Brown Norway Female Rat. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2017 , 72, 152-162	6.4	34
284	Inflammatory and mitochondrial gene expression data in GPER-deficient cardiomyocytes from male and female mice. <i>Data in Brief</i> , 2017 , 10, 465-473	1.2	7
283	Cellular basis of angiotensin-(1-7)-induced augmentation of left ventricular functional performance in heart failure. <i>International Journal of Cardiology</i> , 2017 , 236, 405-412	3.2	22
282	Novel Cardiac Intracrine Mechanisms Based on Ang-(1-12)/Chymase Axis Require a Revision of Therapeutic Approaches in Human Heart Disease. <i>Current Hypertension Reports</i> , 2017 , 19, 16	4.7	31
281	Walmor C. De Mello: "Your Heart Is Still With Us". <i>Hypertension</i> , 2017 , 69, 992-993	8.5	
280	Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease. <i>Pharmacological Research</i> , 2017 , 125, 57-71	10.2	71

279	Increased Inflammation in Pericardial Fluid Persists 48 Hours After Cardiac Surgery. <i>Circulation</i> , 2017 , 136, 2284-2286	16.7	23
278	Cardiomyocyte-specific deletion of the G protein-coupled estrogen receptor (GPER) leads to left ventricular dysfunction and adverse remodeling: A sex-specific gene profiling analysis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2017 , 1863, 1870-1882	6.9	33
277	Blunting of cardioprotective actions of estrogen in female rodent heart linked to altered expression of cardiac tissue chymase and ACE2. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2017 , 18, 1470320317722270	3	25
276	Role of Tissue Renin-angiotensin System and the Chymase/angiotensin-(1-12) Axis in the Pathogenesis of Diabetic Retinopathy. <i>Current Medicinal Chemistry</i> , 2017 , 24, 3104-3114	4.3	15
275	Intracellular angiotensin-(1-12) changes the electrical properties of intact cardiac muscle. <i>Molecular and Cellular Biochemistry</i> , 2016 , 422, 31-40	4.2	16
274	Increased fibroblast chymase production mediates procollagen autophagic digestion in volume overload. <i>Journal of Molecular and Cellular Cardiology</i> , 2016 , 92, 1-9	5.8	25
273	Mast Cell Inhibition Attenuates Cardiac Remodeling and Diastolic Dysfunction in Middle-aged, Ovariectomized Fischer 344 Brown Norway Rats. <i>Journal of Cardiovascular Pharmacology</i> , 2016 , 68, 49-57	3.1	17
272	Cardiac remodelling and RAS inhibition. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2016 , 10, 162-713.4	3.4	67
271	Cardiac angiotensin-(1-12) expression and systemic hypertension in rats expressing the human angiotensinogen gene. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2016 , 310, H995-1002 ²²	5.2	22
270	Intracrine angiotensin II functions originate from noncanonical pathways in the human heart. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2016 , 311, H404-14	5.2	49
269	Primacy of cardiac chymase over angiotensin converting enzyme as an angiotensin-(1-12) metabolizing enzyme. <i>Biochemical and Biophysical Research Communications</i> , 2016 , 478, 559-64	3.4	33
268	Modulation of cardiac L-type Ca ²⁺ current by angiotensin-(1-7): normal versus heart failure. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2015 , 9, 342-53	3.4	18
267	Differential expression of the angiotensin-(1-12)/chymase axis in human atrial tissue. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2015 , 9, 168-80	3.4	22
266	Renin-angiotensin-aldosterone system gender differences in an Afro-Caribbean population. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2015 , 16, 539-46	3	14
265	Role of mineralocorticoid receptor antagonists in cardiovascular disease. <i>Circulation Research</i> , 2015 , 116, 206-13	15.7	55
264	ACE2: angiotensin II/angiotensin-(1-7) balance in cardiac and renal injury. <i>Current Hypertension Reports</i> , 2014 , 16, 420	4.7	83
263	Angiotensin-(1-12): a chymase-mediated cellular angiotensin II substrate. <i>Current Hypertension Reports</i> , 2014 , 16, 429	4.7	47
262	Salt Loading Promotes Kidney Injury via Fibrosis in Young Female Ren2 Rats. <i>CardioRenal Medicine</i> , 2014 , 4, 43-52	2.8	7

261	Statin treatment in hypercholesterolemic men does not attenuate angiotensin II-induced venoconstriction. <i>PLoS ONE</i> , 2014 , 9, e103909	3.7	4
260	Clinical utility of fixed-dose combinations in hypertension: evidence for the potential of nebivolol/valsartan. <i>Integrated Blood Pressure Control</i> , 2014 , 7, 61-70	3.5	4
259	An evolving story of angiotensin-II-forming pathways in rodents and humans. <i>Clinical Science</i> , 2014 , 126, 461-9	6.5	75
258	Impact of performance improvement continuing medical education on cardiometabolic risk factor control: the COSEHC initiative. <i>Journal of Continuing Education in the Health Professions</i> , 2014 , 34, 25-36	2.1	3
257	Comparative effects of a novel angiotensin-converting enzyme inhibitor versus captopril on plasma angiotensins after myocardial infarction. <i>Pharmacology</i> , 2014 , 94, 21-8	2.3	10
256	Chymase mediates injury and mitochondrial damage in cardiomyocytes during acute ischemia/reperfusion in the dog. <i>PLoS ONE</i> , 2014 , 9, e94732	3.7	34
255	Chymase mediates angiotensin-(1-12) metabolism in normal human hearts. <i>Journal of the American Society of Hypertension</i> , 2013 , 7, 128-36		51
254	Hemodynamic and hormonal changes to dual renin-angiotensin system inhibition in experimental hypertension. <i>Hypertension</i> , 2013 , 61, 417-24	8.5	43
253	Salt loading exacerbates diastolic dysfunction and cardiac remodeling in young female Ren2 rats. <i>Metabolism: Clinical and Experimental</i> , 2013 , 62, 1761-71	12.7	9
252	Renin inhibition and AT(1)R blockade improve metabolic signaling, oxidant stress and myocardial tissue remodeling. <i>Metabolism: Clinical and Experimental</i> , 2013 , 62, 861-72	12.7	20
251	Hemodynamic and hormonal patterns of untreated essential hypertension in men and women. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2013 , 7, 293-305	3.4	18
250	Primacy of angiotensin converting enzyme in angiotensin-(1-12) metabolism. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2013 , 305, H644-50	5.2	22
249	Response to "Angiotensin-(1-7) in the central regulation of blood pressure and renin-angiotensin system". <i>American Journal of Hypertension</i> , 2013 , 26, 1175	2.3	
248	Clinical and economic outcomes associated with amlodipine/renin-angiotensin system blocker combinations. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2013 , 7, 27-39	3.4	15
247	Predominance of AT(1) blockade over mas-mediated angiotensin-(1-7) mechanisms in the regulation of blood pressure and renin-angiotensin system in mRen2.Lewis rats. <i>American Journal of Hypertension</i> , 2013 , 26, 583-90	2.3	26
246	The COSEHC Global Vascular Risk Management quality improvement program: first follow-up report. <i>Vascular Health and Risk Management</i> , 2013 , 9, 391-400	4.4	2
245	Characterization of the cardiac renin angiotensin system in oophorectomized and estrogen-replete mRen2.Lewis rats. <i>PLoS ONE</i> , 2013 , 8, e76992	3.7	38
244	Role of Chymase in Matrix and Myocardial Remodeling Due to Mitral Regurgitation: Implications for Therapy 2013 , 201-214		

243	Combination of direct renin inhibition with angiotensin type 1 receptor blockade improves aldosterone but does not improve kidney injury in the transgenic Ren2 rat. <i>Regulatory Peptides</i> , 2012 , 176, 36-44		15
242	Emergency department patients self-report higher patient inertia, hopelessness, and harmful lifestyle choices than community counterparts. <i>Journal of Clinical Hypertension</i> , 2012 , 14, 828-35	2.3	4
241	Restoration of the blood pressure circadian rhythm by direct renin inhibition and blockade of angiotensin II receptors in mRen2.Lewis hypertensive rats. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2012 , 6, 15-29	3.4	13
240	Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the transgenic (mRen2) rat. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2012 , 302, H2341-51	5.2	41
239	Low glial angiotensinogen improves body habitus, diastolic function, and exercise tolerance in aging male rats. <i>Cardiovascular Endocrinology</i> , 2012 , 1, 49-58		7
238	Mineralocorticoid receptor-dependent proximal tubule injury is mediated by a redox-sensitive mTOR/S6K1 pathway. <i>American Journal of Nephrology</i> , 2012 , 35, 90-100	4.6	21
237	Cardiac kallikrein-kinin system is upregulated in chronic volume overload and mediates an inflammatory induced collagen loss. <i>PLoS ONE</i> , 2012 , 7, e40110	3.7	42
236	Nebivolol reduces cardiac angiotensin II, associated oxidative stress and fibrosis but not arterial pressure in salt-loaded spontaneously hypertensive rats. <i>Journal of Hypertension</i> , 2012 , 30, 1766-74	1.9	30
235	Effects of combination therapy with valsartan and aliskiren on arterial pressure, cardiac hypertrophy and urinary protein excretion in hypertensive rats. <i>FASEB Journal</i> , 2012 , 26, 1105.4	0.9	
234	Differential effects of ACE and chymase in the metabolism of exogenous angiotensin-(1-12) in Wistar-Kyoto rats. <i>FASEB Journal</i> , 2012 , 26, 1105.3	0.9	
233	Chymase-dependent generation of angiotensin II from angiotensin-(1-12) in human atrial tissue. <i>PLoS ONE</i> , 2011 , 6, e28501	3.7	94
232	ACE2: more of Ang-(1-7) or less Ang II?. <i>Current Opinion in Nephrology and Hypertension</i> , 2011 , 20, 1-6	3.5	111
231	Nebivolol improves insulin sensitivity in the TGR(Ren2)27 rat. <i>Metabolism: Clinical and Experimental</i> , 2011 , 60, 1757-66	12.7	19
230	Angiotensin II activation of mTOR results in tubulointerstitial fibrosis through loss of N-cadherin. <i>American Journal of Nephrology</i> , 2011 , 34, 115-25	4.6	36
229	Attenuation of hypertension-mediated glomerulosclerosis in conjunction with increased angiotensin (1-7). <i>Therapeutic Advances in Cardiovascular Disease</i> , 2011 , 5, 297-304	3.4	8
228	Sex differences in baroreflex sensitivity, heart rate variability, and end organ damage in the TGR(mRen2)27 rat. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2011 , 301, H1540-50	5.2	25
227	Uptake and metabolism of the novel peptide angiotensin-(1-12) by neonatal cardiac myocytes. <i>PLoS ONE</i> , 2011 , 6, e15759	3.7	45
226	Role of olmesartan in combination therapy in blood pressure control and vascular function. <i>Vascular Health and Risk Management</i> , 2010 , 6, 701-9	4.4	3

225	COSEHC global vascular risk management quality improvement program: rationale and design. <i>Vascular Health and Risk Management</i> , 2010 , 6, 1135-45	4.4	3
224	Decreased cardiac Ang-(1-7) is associated with salt-induced cardiac remodeling and dysfunction. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2010 , 4, 17-25	3.4	18
223	Individualizing hypertension treatment with impedance cardiography: a meta-analysis of published trials. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2010 , 4, 5-16	3.4	31
222	ARBITER 6-HALTS. Does it have the power to settle all matters?. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2010 , 4, 77-81	3.4	
221	New physiological concepts of the renin-angiotensin system from the investigation of precursors and products of angiotensin I metabolism. <i>Hypertension</i> , 2010 , 55, 445-52	8.5	92
220	The ANG-(1-7)/ACE2/mas axis in the regulation of nephron function. <i>American Journal of Physiology - Renal Physiology</i> , 2010 , 298, F1297-305	4.3	113
219	Comparative effect of direct renin inhibition and AT1R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat. <i>American Journal of Physiology - Renal Physiology</i> , 2010 , 298, F655-61	4.3	34
218	Angiotensin-(1-12) requires angiotensin converting enzyme and AT1 receptors for cardiovascular actions within the solitary tract nucleus. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2010 , 299, H763-71	5.2	40
217	Inhibition of angiotensin-converting enzyme 2 exacerbates cardiac hypertrophy and fibrosis in Ren-2 hypertensive rats. <i>American Journal of Hypertension</i> , 2010 , 23, 687-93	2.3	48
216	Salt-induced renal injury in spontaneously hypertensive rats: effects of nebivolol. <i>American Journal of Nephrology</i> , 2010 , 32, 557-66	4.6	34
215	Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension. <i>Hypertension</i> , 2010 , 55, 90-8	8.5	226
214	Nebivolol attenuates maladaptive proximal tubule remodeling in transgenic rats. <i>American Journal of Nephrology</i> , 2010 , 31, 262-72	4.6	13
213	Advances in the renin angiotensin system focus on angiotensin-converting enzyme 2 and angiotensin-(1-7). <i>Advances in Pharmacology</i> , 2010 , 59, 197-233	5.7	51
212	Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control. <i>Life Sciences</i> , 2010 , 86, 289-99	6.8	34
211	The impact of changing ICD code on hypertension-related mortality in the southeastern United States from 1994-2005. <i>Journal of Clinical Hypertension</i> , 2010 , 12, 213-22	2.3	2
210	Angiotensin-(1-7), Angiotensin-Converting Enzyme 2, and New Components of the Renin Angiotensin System 2010 , 121-133		
209	Chymase-dependent generation of Angiotensin II from Angiotensin-(1-12) in human atrial tissue. <i>FASEB Journal</i> , 2010 , 24, 605.4	0.9	1
208	Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil. <i>Vascular Health and Risk Management</i> , 2009 , 5, 301-14	4.4	28

207	Nebivolol reduces proteinuria and renal NADPH oxidase-generated reactive oxygen species in the transgenic Ren2 rat. <i>American Journal of Nephrology</i> , 2009 , 30, 354-60	4.6	49
206	Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression. <i>Endocrinology</i> , 2009 , 150, 2561-8	4.8	83
205	Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat. <i>American Journal of Physiology - Renal Physiology</i> , 2009 , 296, F1013-22	4.3	36
204	Differential regulation of angiotensin-(1-12) in plasma and cardiac tissue in response to bilateral nephrectomy. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2009 , 296, H1184-92	5.2	63
203	Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic (mRen2)27 rat. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2009 , 297, H1128-39	5.2	22
202	Chronic immunoneutralization of brain angiotensin-(1-12) lowers blood pressure in transgenic (mRen2)27 hypertensive rats. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2009 , 297, R111-5	3.2	35
201	Mineralocorticoid receptor antagonism attenuates vascular apoptosis and injury via rescuing protein kinase B activation. <i>Hypertension</i> , 2009 , 53, 158-65	8.5	32
200	Therapeutic targets in liver transplantation: angiotensin II in nonsteatotic grafts and angiotensin-(1-7) in steatotic grafts. <i>American Journal of Transplantation</i> , 2009 , 9, 439-51	8.7	24
199	Oxidative stress-mediated mitochondrial dysfunction contributes to angiotensin II-induced nonalcoholic fatty liver disease in transgenic Ren2 rats. <i>American Journal of Pathology</i> , 2009 , 174, 1329-37 ⁸	5.8	48
198	Self-reported influences of hopelessness, health literacy, lifestyle action, and patient inertia on blood pressure control in a hypertensive emergency department population. <i>American Journal of the Medical Sciences</i> , 2009 , 338, 368-72	2.2	29
197	Salt and Heart: RAAS Involvement 2009 , 165-173		
196	Newer Insights into the Biochemical Physiology of the Renin-Angiotensin System: Role of Angiotensin-(1-7), Angiotensin Converting Enzyme 2, and Angiotensin-(1-12) 2009 , 7-17		
195	The Renin-Angiotensin System and the Heart 2009 , 181-188		0
194	Mineralocorticoid Receptor (MR) Antagonism Attenuates Glomerular Filtration Barrier Remodeling in the Transgenic Ren2 Rat. <i>FASEB Journal</i> , 2009 , 23, 803.16	0.9	
193	Distinct roles for angiotensin-converting enzyme 2 and carboxypeptidase A in the processing of angiotensins within the murine heart. <i>Experimental Physiology</i> , 2008 , 93, 613-21	2.4	48
192	Injections of angiotensin-converting enzyme 2 inhibitor MLN4760 into nucleus tractus solitarii reduce baroreceptor reflex sensitivity for heart rate control in rats. <i>Experimental Physiology</i> , 2008 , 93, 694-700	2.4	66
191	Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats. <i>Journal of Hepatology</i> , 2008 , 49, 417-28	13.4	77
190	Angiotensin II AT1 receptor blockade normalizes CD11b+ monocyte production in bone marrow of hypercholesterolemic monkeys. <i>Atherosclerosis</i> , 2008 , 196, 624-32	3.1	25

189	Differential effect of low dose thiazides on the Renin Angiotensin system in genetically hypertensive and normotensive rats. <i>Journal of the American Society of Hypertension</i> , 2008 , 2, 106-15		23
188	Reversal of vascular hypertrophy in hypertensive patients through blockade of angiotensin II receptors. <i>Journal of the American Society of Hypertension</i> , 2008 , 2, 165-72		46
187	Administration of D-Alanine-[Ang-(1-7)] (A-779) Prior to Pregnancy in Sprague Dawley Rats Produces Antidiuresis in Late Gestation. <i>Journal of the American Society of Hypertension</i> , 2008 , 2, 425-430		4
186	Angiotensin-(1-12) is an alternate substrate for angiotensin peptide production in the heart. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2008 , 294, H2242-7	5.2	75
185	Estrogen, nitric oxide, and hypertension differentially modulate agonist-induced contractile responses in female transgenic (mRen2)27 hypertensive rats. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2008 , 294, H1995-2001	5.2	17
184	Sex differences in circulating and renal angiotensins of hypertensive mRen(2). Lewis but not normotensive Lewis rats. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2008 , 295, H10-20	5.2	92
183	Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2008 , 295, E110-6	6	85
182	Effect of renin inhibition and AT1R blockade on myocardial remodeling in the transgenic Ren2 rat. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2008 , 295, E103-9	6	50
181	MAP kinase/phosphatase pathway mediates the regulation of ACE2 by angiotensin peptides. <i>American Journal of Physiology - Cell Physiology</i> , 2008 , 295, C1169-74	5.4	84
180	Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-kappaB activation via NADPH oxidase. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2008 , 294, E345-51	6	159
179	Regulation of ACE2 in cardiac myocytes and fibroblasts. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2008 , 295, H2373-9	5.2	175
178	Localization of the novel angiotensin peptide, angiotensin-(1-12), in heart and kidney of hypertensive and normotensive rats. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2008 , 294, H2614-8	5.2	64
177	ACE2 and ANG-(1-7) in the rat uterus during early and late gestation. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2008 , 294, R151-61	3.2	74
176	Angiotensin-(1-7) serves as an aquaretic by increasing water intake and diuresis in association with downregulation of aquaporin-1 during pregnancy in rats. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2008 , 294, R1073-80	3.2	23
175	Attenuation of NADPH oxidase activation and glomerular filtration barrier remodeling with statin treatment. <i>Hypertension</i> , 2008 , 51, 474-80	8.5	83
174	Renin inhibition attenuates insulin resistance, oxidative stress, and pancreatic remodeling in the transgenic Ren2 rat. <i>Endocrinology</i> , 2008 , 149, 5643-53	4.8	65
173	Activation of local chorionic villi angiotensin II levels but not angiotensin (1-7) in preeclampsia. <i>Hypertension</i> , 2008 , 51, 1066-72	8.5	76
172	Modulation of reflex function by endogenous angiotensins in older transgenic rats with low glial angiotensinogen. <i>Hypertension</i> , 2008 , 51, 1326-31	8.5	29

171	Olmесartan for the treatment of arterial hypertension. <i>Future Cardiology</i> , 2008 , 4, 357-72	1.3	8
170	Increased expression of angiotensin converting enzyme 2 in conjunction with reduction of neointima by angiotensin II type 1 receptor blockade. <i>Hypertension Research</i> , 2008 , 31, 553-9	4.7	69
169	Angiotensin-(1-7) and baroreflex function in nucleus tractus solitarii of (mRen2)27 transgenic rats. <i>Journal of Cardiovascular Pharmacology</i> , 2008 , 51, 542-8	3.1	45
168	New angiotensins. <i>Journal of Molecular Medicine</i> , 2008 , 86, 663-71	5.5	63
167	Characterization of vascular reactivity in dorsal hand veins after oral rosiglitazone treatment in healthy subjects. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2008 , 46, 30-9	2	5
166	Experimental Hypertension is Associated with Differential Expression of Angiotensin-(1 β 2) in Heart of Hypertensive and Normotensive Rats. <i>FASEB Journal</i> , 2008 , 22, 1210.20	0.9	
165	Exogenous Angiotensin-(1 β 2) Impairs Baroreflex Sensitivity in the Solitary Tract Nucleus in Anesthetized Sprague-Dawley Rats. <i>FASEB Journal</i> , 2008 , 22,	0.9	1
164	Female gender is associated with decreased oxidative stress and increased insulin-stimulated glucose uptake in skeletal muscle in TGR(mRen-2)27 rats. <i>FASEB Journal</i> , 2008 , 22, 1226.33	0.9	
163	Renin Inhibition Attenuates Ang II Induced Oxidative Stress and Remodeling in the Pancreas of the Ren2 Rat (tg (mREN2)27). <i>FASEB Journal</i> , 2008 , 22, 758.12	0.9	
162	Inhibition of the PI3 Kinase Signal Transduction Pathway in Nucleus Tractus Solitarii of (mRen2)27 Transgenic Rats improves Baroreceptor Sensitivity. <i>FASEB Journal</i> , 2008 , 22, 737.38	0.9	1
161	Chronic Intracerebroventricular AT1 Receptor Blockade, but not Renin Inhibition, Normalizes Blood Pressure in (mRen2)27 Transgenic Rats. <i>FASEB Journal</i> , 2008 , 22,	0.9	3
160	The role of noninvasive hemodynamic monitoring in the evaluation and treatment of hypertension. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2007 , 1, 113-8	3.4	7
159	Angiotensin-(1-7): pharmacology and new perspectives in cardiovascular treatments. <i>Cardiovascular Drug Reviews</i> , 2007 , 25, 162-74		89
158	Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, decreases cardiac oxidative stress and remodeling in Ren2 transgenic rats. <i>Endocrinology</i> , 2007 , 148, 2181-8	4.8	65
157	Baroreceptor reflex regulation in anesthetized transgenic rats with low glia-derived angiotensinogen. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007 , 292, H1412-9	5.2	33
156	Temporal-spatial expression of ANG-(1-7) and angiotensin-converting enzyme 2 in the kidney of normal and hypertensive pregnant rats. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2007 , 293, R169-77	3.2	67
155	Proximal tubule microvilli remodeling and albuminuria in the Ren2 transgenic rat. <i>American Journal of Physiology - Renal Physiology</i> , 2007 , 292, F861-7	4.3	25
154	Angiotensin II-mediated oxidative stress promotes myocardial tissue remodeling in the transgenic (mRen2) 27 Ren2 rat. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007 , 293, E355-63 ⁶		79

153	Angiotensin metabolism in renal proximal tubules, urine, and serum of sheep: evidence for ACE2-dependent processing of angiotensin II. <i>American Journal of Physiology - Renal Physiology</i> , 2007 , 292, F82-91	4.3	115
152	Primary role of angiotensin-converting enzyme-2 in cardiac production of angiotensin-(1-7) in transgenic Ren-2 hypertensive rats. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007 , 292, H3019-24	5.2	48
151	Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling. <i>Endocrinology</i> , 2007 , 148, 3773-80	4.8	88
150	Reduced circulating levels of angiotensin-(1-7) in systemic sclerosis: a new pathway in the dysregulation of endothelial-dependent vascular tone control. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 1305-10	2.4	25
149	Beneficial versus harmful effects of Angiotensin (1-7) on impulse propagation and cardiac arrhythmias in the failing heart. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2007 , 8, 74-80	3	47
148	Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2. <i>Cancer Research</i> , 2007 , 67, 2809-15	10.1	117
147	NADPH oxidase contributes to vascular inflammation, insulin resistance, and remodeling in the transgenic (mRen2) rat. <i>Hypertension</i> , 2007 , 50, 384-91	8.5	94
146	Interplay Between ACE2 and Angiotensin-(1-7) in the Regulation of Blood Pressure. <i>Current Hypertension Reviews</i> , 2007 , 3, 97-104	2.3	
145	Comparison of inhibitory effects of irbesartan and atorvastatin treatment on the renin angiotensin system (RAS) in veins: a randomized double-blind crossover trial in healthy subjects. <i>Journal of Clinical Pharmacology</i> , 2007 , 47, 112-20	2.9	23
144	Increased hypothalamic angiotensin-(1-7) levels in rats with aortic coarctation-induced hypertension. <i>Peptides</i> , 2007 , 28, 1580-5	3.8	16
143	Transgenic Rats with Low Brain Renin-Angiotensin System Activity Due to Glial Deficiency Are Protected Against Heart Failure Late in Life. <i>Journal of Cardiac Failure</i> , 2007 , 13, S83	3.3	3
142	Exercise training prevents development of cardiac contractile dysfunction in hypertensive TG (mREN-2)27 rats. <i>Journal of the American Society of Hypertension</i> , 2007 , 1, 393-9		5
141	Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapy. <i>Vascular Health and Risk Management</i> , 2007 , 3, 125-37	4.4	71
140	Aging and the brain renin-angiotensin system: insights from studies in transgenic rats. <i>Cleveland Clinic Journal of Medicine</i> , 2007 , 74 Suppl 1, S95-8	2.8	15
139	Exercise training maintains cardiac output and stroke volume in hypertensive TG (mREN-2)27 rats with impaired diastolic function. <i>FASEB Journal</i> , 2007 , 21, A930	0.9	
138	Decidualization of pseudopregnant uterus is associated with marked reduction in Ang II and Ang-(1-7) content. <i>FASEB Journal</i> , 2007 , 21, A1252	0.9	
137	Treating the cardiometabolic syndrome: an opportunity to provide comprehensive cardiovascular risk reduction. <i>Journal of the Cardiometabolic Syndrome</i> , 2006 , 1, 358-61		6
136	Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. <i>American Journal of Cardiology</i> , 2006 , 98, 121-8	3	376

135	Distribution of angiotensin-(1-7) and ACE2 in human placentas of normal and pathological pregnancies. <i>Placenta</i> , 2006 , 27, 200-7	3.4	162
134	Cardioprotective role for angiotensin-(1-7) and angiotensin converting enzyme 2 in the heart. <i>Future Cardiology</i> , 2006 , 2, 335-42	1.3	13
133	Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2006 , 291, H2166-72	5.2	108
132	Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat. <i>American Journal of Physiology - Renal Physiology</i> , 2006 , 291, F1308-14	4.3	94
131	Differential expression of nuclear AT1 receptors and angiotensin II within the kidney of the male congenic mRen2. Lewis rat. <i>American Journal of Physiology - Renal Physiology</i> , 2006 , 290, F1497-506	4.3	91
130	Distinct roles for ANG II and ANG-(1-7) in the regulation of angiotensin-converting enzyme 2 in rat astrocytes. <i>American Journal of Physiology - Cell Physiology</i> , 2006 , 290, C420-6	5.4	146
129	Angiotensin-converting enzyme 2 and angiotensin-(1-7): an evolving story in cardiovascular regulation. <i>Hypertension</i> , 2006 , 47, 515-21	8.5	198
128	Value of noninvasive hemodynamics to achieve blood pressure control in hypertensive subjects. <i>Hypertension</i> , 2006 , 47, 771-7	8.5	68
127	Influence of gender and genetic variability on plasma angiotensin peptides. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2006 , 7, 92-7	3	42
126	Cost-effectiveness of impedance cardiography testing in uncontrolled hypertension. <i>The American Heart Hospital Journal</i> , 2006 , 4, 279-89		4
125	Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2006 , 7, 3-14	3	148
124	The protective effects of angiotensin II blockade with olmesartan medoxomil on resistance vessel remodeling (The VIOS study): rationale and baseline characteristics. <i>American Journal of Cardiovascular Drugs</i> , 2006 , 6, 335-42	4	26
123	Diabetes, hypertension, and dyslipidemia in Mexican Americans and non-Hispanic whites. <i>American Journal of Preventive Medicine</i> , 2006 , 30, 103-10	6.1	55
122	Effect of estrogen on neprilysin expression in uterus and kidney of Sprague-Dawley normotensive and heterozygous (mRen2) ²⁷ -transgenic hypertensive rats. <i>Peptides</i> , 2006 , 27, 2912-8	3.8	16
121	ACE and ACE2: their role to balance the expression of angiotensin II and angiotensin-(1-7). <i>Kidney International</i> , 2006 , 70, 8-10	9.9	55
120	Rats with low brain angiotensinogen do not exhibit insulin resistance during early aging. <i>Endocrine</i> , 2006 , 30, 167-74		19
119	Reduced Formation of Ang-(1-7) by ACE2 in Dorsal Medulla Oblongata of Sprague-Dawley (SD) and ASrAogen Rats During Aging. <i>FASEB Journal</i> , 2006 , 20, A1209	0.9	
118	Impaired Baroreceptor Reflex Function of Older ASrAOGEN Rats. <i>FASEB Journal</i> , 2006 , 20, A1209	0.9	

117	Divergent regulation of circulating and intrarenal renin-angiotensin systems in response to long-term blockade. <i>American Journal of Nephrology</i> , 2005 , 25, 335-41	4.6	22
116	Allelic variants of the human scavenger receptor class B type 1 and paraoxonase 1 on coronary heart disease: genotype-phenotype correlations. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005 , 25, 854-60	9.4	60
115	Noninvasive hemodynamic profiles in hypertensive subjects. <i>American Journal of Hypertension</i> , 2005 , 18, 51S-59S	2.3	27
114	Role of blood pressure reduction in prevention of cardiac and vascular hypertrophy. <i>American Journal of Hypertension</i> , 2005 , 18, 922-9	2.3	26
113	Targeting the RAAS for the treatment of atherosclerosis. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2005 , 2, 221-229		4
112	Addressing the global cardiovascular risk of hypertension, dyslipidemia, and insulin resistance in the southeastern United States. <i>American Journal of the Medical Sciences</i> , 2005 , 329, 276-91	2.2	39
111	Addressing the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome in the southeastern United States, part II: treatment recommendations for management of the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome. <i>American Journal of the Medical Sciences</i> , 2005 , 329, 292-305	2.2	64
110	Myocardial infarction increases ACE2 expression in rat and humans. <i>European Heart Journal</i> , 2005 , 26, 1141; author reply 1141-3	9.5	10
109	Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. <i>Kidney International</i> , 2005 , 68, 2189-96	9.9	198
108	Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. <i>Experimental Physiology</i> , 2005 , 90, 783-90	2.4	186
107	Growth, metabolism, and blood pressure disturbances during aging in transgenic rats with altered brain renin-angiotensin systems. <i>Physiological Genomics</i> , 2005 , 23, 311-7	3.6	55
106	Angiotensin-(1-7) 2005 , 100-110		6
105	Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2005 , 289, H1013-9	5.2	167
104	Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2005 , 289, H2281-90	5.2	292
103	Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2005 , 288, E353-9	6	138
102	Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2005 , 289, H1560-6	5.2	265
101	Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. <i>Circulation</i> , 2005 , 111, 2605-10	16.7	1135
100	Impaired heart rate baroreflex in older rats: role of endogenous angiotensin-(1-7) at the nucleus tractus solitarii. <i>Hypertension</i> , 2005 , 46, 333-40	8.5	74

99	Novel aspects of the renal renin-angiotensin system: angiotensin-(1-7), ACE2 and blood pressure regulation. <i>Contributions To Nephrology</i> , 2004 , 143, 77-89	1.6	60
98	All antagonists in hypertension, heart failure, and diabetic nephropathy: focus on losartan. <i>Current Medical Research and Opinion</i> , 2004 , 20, 279-93	2.5	17
97	Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. <i>Hypertension</i> , 2004 , 43, 970-6	8.5	441
96	Alterations in sympathetic ganglionic transmission in response to angiotensin II in (mRen2) ²⁷ transgenic rats. <i>Hypertension</i> , 2004 , 43, 270-5	8.5	11
95	Angiotensin II stimulates arachidonic acid release from bone marrow stromal cells. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2004 , 5, 176-82	3	18
94	Renin-angiotensin system expression in rat bone marrow haematopoietic and stromal cells. <i>British Journal of Haematology</i> , 2004 , 126, 120-6	4.5	99
93	Vascular responses to Angiotensin-(1-7) during the estrous cycle. <i>Endocrine</i> , 2004 , 24, 161-5		14
92	Central depletion of angiotensinogen is associated with elevated AT1 receptors in the SFO and PVN. <i>Neurotoxicity Research</i> , 2004 , 6, 259-65	4.3	12
91	The role of angiotensin antagonism in stroke prevention in patients with hypertension: focus on losartan. <i>Current Medical Research and Opinion</i> , 2004 , 20, 1797-804	2.5	10
90	Renin-angiotensin system as a therapeutic target in managing atherosclerosis. <i>American Journal of Therapeutics</i> , 2004 , 11, 44-53	1	34
89	COSEHC overview. <i>American Journal of the Medical Sciences</i> , 2004 , 327, 233	2.2	1
88	Estrogen or the AT1 antagonist olmesartan reverses the development of profound hypertension in the congenic mRen2. Lewis rat. <i>Hypertension</i> , 2003 , 42, 781-6	8.5	76
87	Pregnancy enhances the angiotensin (Ang)-(1-7) vasodilator response in mesenteric arteries and increases the renal concentration and urinary excretion of Ang-(1-7). <i>Endocrinology</i> , 2003 , 144, 3338-43	4.8	41
86	Angiotensin receptors contribute to blood pressure homeostasis in salt-depleted SHR. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2003 , 284, R164-73	3.2	24
85	Contribution of angiotensin-(1-7) to cardiovascular physiology and pathology. <i>Current Hypertension Reports</i> , 2003 , 5, 129-34	4.7	43
84	Characterization of angiotensin-(1-7) receptor subtype in mesenteric arteries. <i>Peptides</i> , 2003 , 24, 455-62	3.8	34
83	Cardiac angiotensin-(1-7) in ischemic cardiomyopathy. <i>Circulation</i> , 2003 , 108, 2141-6	16.7	114
82	Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. <i>Archives of Internal Medicine</i> , 2003 , 163, 525-41		314

81	Enhanced renal immunocytochemical expression of ANG-(1-7) and ACE2 during pregnancy. <i>Hypertension</i> , 2003 , 42, 749-53	8.5	112
80	Angiotensin-converting enzyme 2 is an essential regulator of heart function. <i>Nature</i> , 2002 , 417, 822-8	50.4	1345
79	Vasopeptidase inhibition and Ang-(1-7) in the spontaneously hypertensive rat. <i>Kidney International</i> , 2002 , 62, 1349-57	9.9	80
78	Angiotensin-(1-7) in normal and preeclamptic pregnancy. <i>Endocrine</i> , 2002 , 18, 239-45		156
77	Angiotensin peptides modulate bradykinin levels in the interstitium of the dog heart in vivo. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002 , 300, 324-9	4.7	30
76	Blood pressure-independent attenuation of cardiac hypertrophy by AT(1)R-AS gene therapy. <i>Hypertension</i> , 2002 , 39, 969-75	8.5	43
75	The hypertension-lipid connection: insights into the relation between angiotensin II and cholesterol in atherogenesis. <i>American Journal of the Medical Sciences</i> , 2002 , 323, 17-24	2.2	36
74	Mechanisms linking angiotensin II and atherogenesis. <i>Current Opinion in Lipidology</i> , 2002 , 13, 505-12	4.4	59
73	Sexual dysfunction in patients with hypertension: implications for therapy. <i>Journal of Clinical Hypertension</i> , 2002 , 4, 424-32	2.3	50
72	Use of angiotensin II receptor blockers in animal models of atherosclerosis. <i>American Journal of Hypertension</i> , 2002 , 15, 9S-13S	2.3	44
71	Effects of omapatrilat on the renin-angiotensin system in salt-sensitive hypertension. <i>American Journal of Hypertension</i> , 2002 , 15, 557-64	2.3	70
70	The angiotensin II AT1 receptor antagonist irbesartan prevents thromboxane A2-induced vasoconstriction in the rat hind-limb vascular bed in vivo. <i>Journal of Hypertension</i> , 2001 , 19, 561-6	1.9	11
69	Pathways of angiotensin-(1-7) metabolism in the kidney. <i>Nephrology Dialysis Transplantation</i> , 2001 , 16 Suppl 1, 22-6	4.3	55
68	Omapatrilat versus lisinopril: efficacy and neurohormonal profile in salt-sensitive hypertensive patients. <i>Hypertension</i> , 2001 , 38, 1342-8	8.5	52
67	Urinary vasodilator and vasoconstrictor angiotensins during menstrual cycle, pregnancy, and lactation. <i>Endocrine</i> , 2001 , 16, 117-22		56
66	Association of angiotensinogen M235T and A(-6)G gene polymorphisms with coronary heart disease with independence of essential hypertension: the PROCAGENE study. Prospective Cardiac Gene. <i>Journal of the American College of Cardiology</i> , 2001 , 37, 1536-42	15.1	72
65	Inhibition of platelet aggregability by losartan in essential hypertension. <i>American Journal of Cardiology</i> , 2000 , 86, 1188-92	3	57
64	Pathways for angiotensin-(1-7) metabolism in pulmonary and renal tissues. <i>American Journal of Physiology - Renal Physiology</i> , 2000 , 279, F841-50	4.3	100

63	Differential actions of renal ischemic injury on the intrarenal angiotensin system. <i>American Journal of Physiology - Renal Physiology</i> , 2000 , 279, F636-45	4.3	86
62	Angiotensin-converting enzyme expression in human carotid artery atherosclerosis. <i>Hypertension</i> , 2000 , 35, 353-9	8.5	89
61	Contribution of angiotensin-(1-7) to blood pressure regulation in salt-depleted hypertensive rats. <i>Hypertension</i> , 2000 , 36, 417-22	8.5	78
60	Using Angiotensin Converting Enzyme Inhibitors in African-American Hypertensives: A New Approach to Treating Hypertension and Preventing Target-Organ Damage. <i>Current Medical Research and Opinion</i> , 2000 , 16, 66-79	2.5	36
59	Release of angiotensin-(1-7) from the rat hindlimb: influence of angiotensin-converting enzyme inhibition. <i>Hypertension</i> , 2000 , 35, 348-52	8.5	53
58	Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. <i>Circulation</i> , 2000 , 101, 1586-93	16.7	253
57	Evidence that prostaglandins mediate the antihypertensive actions of angiotensin-(1-7) during chronic blockade of the renin-angiotensin system. <i>Journal of Cardiovascular Pharmacology</i> , 2000 , 36, 109-17	3.1	74
56	State-of-the-Art lecture. Antiproliferative actions of angiotensin-(1-7) in vascular smooth muscle. <i>Hypertension</i> , 1999 , 34, 950-7	8.5	121
55	Increased central angiotensin and osmotic responses in the Ren-2 transgenic rat. <i>Hypertension</i> , 1999 , 33, 385-8	8.5	11
54	Angiotensin-(1-7) reduces smooth muscle growth after vascular injury. <i>Hypertension</i> , 1999 , 33, 207-11	8.5	155
53	Differential response of angiotensin peptides in the urine of hypertensive animals. <i>Regulatory Peptides</i> , 1999 , 80, 57-66		33
52	Consortium for Southeastern Hypertension Control. <i>American Journal of the Medical Sciences</i> , 1999 , 318, 357	2.2	24
51	Differential actions of angiotensin-(1-7) in the kidney. <i>Kidney International</i> , 1998 , 68, S3-6	9.9	31
50	Angiotensin-(1-7) immunoreactivity in the hypothalamus of the (mRen-2d)27 transgenic rat. <i>Brain Research</i> , 1998 , 798, 36-45	3.7	36
49	Angiotensin-(1-7): a bioactive fragment of the renin-angiotensin system. <i>Regulatory Peptides</i> , 1998 , 78, 13-8		99
48	Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. <i>Hypertension</i> , 1998 , 31, 356-61	8.5	193
47	Metabolism of angiotensin-(1-7) by angiotensin-converting enzyme. <i>Hypertension</i> , 1998 , 31, 362-7	8.5	242
46	Converting enzyme determines plasma clearance of angiotensin-(1-7). <i>Hypertension</i> , 1998 , 32, 496-502	8.5	154

45	Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan. <i>Hypertension</i> , 1998 , 31, 699-705	8.5	196
44	NK1 receptor antagonist blocks angiotensin II responses in renin transgenic rat medulla oblongata. <i>Hypertension</i> , 1998 , 31, 473-9	8.5	30
43	Role of nitric oxide in the evolution of renal ischemia in two-kidney, one-clip renovascular hypertension. <i>Hypertension Research</i> , 1998 , 21, 267-77	4.7	14
42	Cardiovascular, endocrine, and body fluid-electrolyte responses to salt loading in mRen-2 transgenic rats. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1998 , 275, H1130-7	5.2	14
41	Angiotensin II acts at AT1 receptors in the nucleus of the solitary tract to attenuate the baroreceptor reflex. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 1998 , 275, R1611-9	3.2	62
40	Role of AT1 and AT2 receptors in the plasma clearance of angiotensin II. <i>Journal of Cardiovascular Pharmacology</i> , 1998 , 31, 464-9	3.1	28
39	Losartan inhibits thromboxane A2-induced platelet aggregation and vascular constriction in spontaneously hypertensive rats. <i>Journal of Cardiovascular Pharmacology</i> , 1998 , 32, 198-205	3.1	67
38	Hypothalamic substance P release. Attenuated angiotensin responses in mRen2(27) transgenic rats. <i>Hypertension</i> , 1997 , 29, 510-3	8.5	19
37	Bovine aortic endothelial cells contain an angiotensin-(1-7) receptor. <i>Hypertension</i> , 1997 , 29, 388-93	8.5	121
36	Effects of chronic hormone replacement on the renin-angiotensin system in cynomolgus monkeys. <i>Journal of Hypertension</i> , 1997 , 15, 719-26	1.9	49
35	Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. <i>Hypertension</i> , 1997 , 29, 394-400	8.5	215
34	Chronic estrogen treatment in female transgenic (mRen2)27 hypertensive rats augments endothelium-derived nitric oxide release. <i>American Journal of Hypertension</i> , 1997 , 10, 662-70	2.3	21
33	Estrogen protects transgenic hypertensive rats by shifting the vasoconstrictor-vasodilator balance of RAS. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 1997 , 273, R1908-15	3.2	75
32	Counterregulatory actions of angiotensin-(1-7). <i>Hypertension</i> , 1997 , 30, 535-41	8.5	366
31	Hypertension-related morbidity and mortality in the southeastern United States. <i>American Journal of the Medical Sciences</i> , 1997 , 313, 195-209	2.2	144
30	Drug Evaluations Cardiovascular & Renal: Biology of angiotensin II receptor inhibition with a focus on losartan: A new drug for the treatment of hypertension. <i>Expert Opinion on Investigational Drugs</i> , 1996 , 5, 1201-1214	5.9	11
29	Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension. <i>Journal of Hypertension</i> , 1996 , 14, 799-805	1.9	184
28	Pathologic consequences of increased angiotensin II activity. <i>Cardiovascular Drugs and Therapy</i> , 1996 , 10, 511-8	3.9	32

27	Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. <i>Hypertension</i> , 1996 , 27, 523-8	8.5	287
26	Salt-sensitive hypertension in (mREN-2) ²⁷ transgenic rats. <i>Hypertension</i> , 1996 , 27, 573-7	8.5	15
25	Angiotensin-(1-7) inhibits vascular smooth muscle cell growth. <i>Hypertension</i> , 1996 , 28, 104-8	8.5	216
24	Angiotensin receptor heterogeneity in the dorsal medulla oblongata as defined by angiotensin-(1-7). <i>Advances in Experimental Medicine and Biology</i> , 1996 , 396, 225-35	3.6	7
23	Angiotensins differentially activate phospholipase D in vascular smooth muscle cells from spontaneously hypertensive and Wistar-Kyoto rats. <i>American Journal of Hypertension</i> , 1995 , 8, 1105-11	2.3	14
22	Angiotensin-(1-7) and nitric oxide interaction in renovascular hypertension. <i>Hypertension</i> , 1995 , 25, 796-802	8.5	75
21	Opposing actions of angiotensin-(1-7) and angiotensin II in the brain of transgenic hypertensive rats. <i>Hypertension</i> , 1995 , 25, 1260-5	8.5	61
20	Pressor and reflex sensitivity is altered in spontaneously hypertensive rats treated with angiotensin-(1-7). <i>Hypertension</i> , 1995 , 26, 1138-44	8.5	57
19	A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11. <i>Life Sciences</i> , 1993 , 52, 1461-80	6.8	212
18	Receptor subtype that mediates the neuronal effects of angiotensin II in the rat dorsal medulla. <i>Brain Research Bulletin</i> , 1993 , 31, 195-200	3.9	27
17	Angiotensin(1-7) in the spontaneously hypertensive rat. <i>Peptides</i> , 1993 , 14, 883-91	3.8	126
16	Cardiovascular actions of angiotensin(1-7). <i>Peptides</i> , 1993 , 14, 679-84	3.8	157
15	Effects of angiotensin analogues and angiotensin receptor antagonists on paraventricular neurones. <i>Regulatory Peptides</i> , 1992 , 38, 111-20		58
14	Evidence that prolyl endopeptidase participates in the processing of brain angiotensin. <i>Journal of Hypertension</i> , 1991 , 9, 631-8	1.9	87
13	Hypertensive mechanisms and converting enzyme inhibitors. <i>Clinical Cardiology</i> , 1991 , 14, IV56-62; discussion IV83-90	3.3	19
12	Reassessment of plasma angiotensins measurement: effects of protease inhibitors and sample handling procedures. <i>Peptides</i> , 1991 , 12, 1135-41	3.8	78
11	Angiotensin-[1-7]. <i>Journal of Cardiovascular Pharmacology</i> , 1990 , 16, S19-S24	3.1	19
10	Importance of the renin-angiotensin-aldosterone system (RAS) in the physiology and pathology of hypertension. An overview. <i>Drugs</i> , 1990 , 39 Suppl 2, 1-8	12.1	28

9	Angiotensin II and angiotensin (1-7) excite neurons in the canine medulla in vitro. <i>Brain Research Bulletin</i> , 1990 , 24, 275-80	3.9	42
8	A hypothesis regarding the function of angiotensin peptides in the brain. <i>Clinical and Experimental Hypertension</i> , 1988 , 10 Suppl 1, 107-21		18
7	Role of area postrema pressor mechanisms in the regulation of arterial pressure. <i>Canadian Journal of Physiology and Pharmacology</i> , 1987 , 65, 1591-7	2.4	46
6	Pressor responses of angiotensin II microinjected into the dorsomedial medulla of the dog. <i>Brain Research</i> , 1987 , 414, 294-300	3.7	34
5	Characterization by high performance liquid chromatography of angiotensin peptides in the plasma and cerebrospinal fluid of the dog. <i>Peptides</i> , 1987 , 8, 939-42	3.8	36
4	Contribution of the vagus nerve to angiotensin II binding sites in the canine medulla. <i>Brain Research Bulletin</i> , 1986 , 17, 497-505	3.9	76
3	Angiotensin and CNS regulation of blood pressure. <i>Clinical and Experimental Hypertension</i> , 1980 , 2, 465-77		16
2	Cardiovascular effects of angiotensin mediated by the central nervous system. <i>Circulation Research</i> , 1972 , 30, 257-62	15.7	318
1	Hemodynamic characteristics of chronic experimental neurogenic hypertension in unanesthetized dogs. <i>Circulation Research</i> , 1969 , 24, 911-22	15.7	77